# Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

> **NCT01895972** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 130 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Latanoprostene bunod

## Key facts

- **NCT ID:** NCT01895972
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-05
- **Primary completion:** 2015-04-02
- **Final completion:** 2015-04-14
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01895972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01895972, "Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01895972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*